INT155265

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.17
First Reported 2001
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 2.62
Pain Relevance 0.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Cd3e) signal transducer activity (Cd3e)
Anatomy Link Frequency
T cells 4
lymphocyte 1
NK cells 1
Cd3e (Mus musculus)
Pain Link Frequency Relevance Heat
adenocard 53 100.00 Very High Very High Very High
ischemia 95 78.08 Quite High
tolerance 1 67.96 Quite High
Pain 2 55.52 Quite High
cytokine 52 48.40 Quite Low
Inflammation 50 46.08 Quite Low
agonist 14 43.40 Quite Low
rheumatoid arthritis 13 26.16 Quite Low
dexamethasone 13 5.00 Very Low Very Low Very Low
chemokine 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 65 100.00 Very High Very High Very High
Lymphatic System Cancer 6 100.00 Very High Very High Very High
Apoptosis 64 96.64 Very High Very High Very High
Malignant Neoplastic Disease 6 95.52 Very High Very High Very High
Metastasis 9 95.28 Very High Very High Very High
Disease 44 95.00 High High
Advanced Or Metastatic Breast Cancer 62 94.28 High High
Suicidal Behaviour 3 93.64 High High
Breast Cancer 46 85.28 High High
Hypoxia 9 82.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These studies revealed that targeting extracellular adenosine generation (cd3?
Regulation (targeting) of cd3 associated with adenocard
1) Confidence 0.17 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.52 Pain Relevance 0.37
Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases.
Regulation (targeting) of CD3 in T cells associated with lymphatic system cancer and disease
2) Confidence 0.16 Published 2009 Journal Bone Marrow Transplant. Section Abstract Doc Link 18850012 Disease Relevance 0.88 Pain Relevance 0.06
The effect of this concentrated lectin preparation on different lymphocyte subpopulations (CD3+, CD4+, CD8+, CD3?
Regulation (effect) of CD3 in lymphocyte
3) Confidence 0.08 Published 2005 Journal Evidence-based Complementary and Alternative Medicine Section Body Doc Link PMC1062151 Disease Relevance 0.07 Pain Relevance 0
is rate-limiting, thereby regulating the amount of TCR/CD3 complex expressed at the cell surface.8,9 In NK cells, the TCR?
Regulation (regulating) of CD3 in NK cells
4) Confidence 0.06 Published 2007 Journal Blood Section Body Doc Link PMC1939810 Disease Relevance 0 Pain Relevance 0
In addition to CD8, we also studied changes of CD3 T cell marker.
Regulation (changes) of CD3 in T cell
5) Confidence 0.06 Published 2001 Journal BMC Dev Biol Section Body Doc Link PMC34117 Disease Relevance 0.42 Pain Relevance 0
Cell numbers of CD3+CD161- T cells were not affected by the treatment.
Neg (not) Regulation (affected) of CD3 in T cells
6) Confidence 0.03 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2956665 Disease Relevance 0 Pain Relevance 0
Ertumaxomab is a trifunctional bispecific antibody – targeting HER2 on tumor cells and CD3 on T cells – that can redirect T cells, macrophages, dendritic cells, and natural killer cells to the sites of tumor metastases [86,87].



Regulation (targeting) of CD3 in T cells associated with cancer and metastasis
7) Confidence 0.03 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2972555 Disease Relevance 0.74 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox